BioNexus Gene Lab (BGLC) vs Sera Prognostics (SERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Sera Prognostics is the larger company by market cap ($72.0 million vs $2.0 million), about 36.1 times the size. BioNexus Gene Lab converts more of its revenue into profit, with a net margin of -40.2% versus -39417.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BGLC | SERA |
|---|---|---|
| Share price | $0.68 | $1.81 |
| Market cap | $1.99M | $71.98M |
| 1-day change | 0.00% | -4.23% |
| YTD return | — | -38.64% |
| 1-year return | — | -43.96% |
| 5-year return | — | -83.55% |
| EPS (TTM) | $-1.26 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.42M | $81.00K |
| Revenue growth (YoY) | -21.93% | +5.19% |
| Net income (latest FY) | $-2.98M | $-31.93M |
| Gross margin | 14.62% | -102.47% |
| Operating margin | -39.93% | -45066.67% |
| Net margin | -40.20% | -39417.28% |
| 52-week high | $4.97 | $3.85 |
| 52-week low | $0.621 | $1.56 |
| Distance from 52-week high | -86.32% | -52.99% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +203.87% |
| Average volume | 6.70K | 27.84K |
| Shares outstanding | 2.93M | 38.80M |
| Employees | 19 | 71 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Sera Prognostics is about 36.1 times larger than BioNexus Gene Lab by market value ($71.98M vs $1.99M).
- BioNexus Gene Lab is more profitable, keeping -40.2 cents of every revenue dollar as net income versus -39417.3 cents for Sera Prognostics.
- Sera Prognostics grew revenue faster in its latest fiscal year (+5.19% vs -21.93%).
About BioNexus Gene Lab
BGLC stock →BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding.
Health Care · Medical Specialities · 19 employees
About Sera Prognostics
SERA stock →Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
Health Care · Medical Specialities · 71 employees
BGLC vs SERA FAQ
Which is bigger, BioNexus Gene Lab or Sera Prognostics?
Sera Prognostics (SERA) is larger, with a market capitalization of $71.98M compared with $1.99M for BioNexus Gene Lab (BGLC).
Are BioNexus Gene Lab and Sera Prognostics in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.